Osteoporosis is still an actual problem, especially in comorbidity and polypharmacy conditions. The method based on the use of dietary supplement OSTEOMED was included in the list of “100 best inventions of Russia” and, according to a number of expert assessments, is the most promising in the treatment of osteoporosis. OSTEOMED is the result of more than 20 years research of Russian scientists. This invention is patented by the international registration system PCT / RU2010 / 000613.
The dietary supplement OSTEOMED contains calcium citrate (the most easily digestible of calcium compounds) and such beekeeping product as the adsorbed drone brood homogenate (HDBA) that is a valuable biologically active organic complex of proteins, amino acids, vitamins, enzymes and micronutrients; for example, it contains more vitamin D than even fish oil. Furthermore, ADBH is the donator of prohormones that are necessary for the bone tissue restoration.
| cysts (bone cavity formations) with osteoporosis before the treatment with OSTEOMED | cyst (bone cavity formation) was closed after the treatment with OSTEOMED |
In addition to the outstanding results in prevention and treatment of osteoporosis, OSTEOMED has been shown to be effective in reducing the pain in bones and joints, preventing the development of sarcopenia, accelerating of fracture healing, improving the hair and nails structure, and maintaining the woman’s health during menopause and postmenopause.
Currently, our company “Parapharm” actively promotes the OSTEOMED to international markets and we are interested in finding partners. As regards the international patenting of OSTEOMED under the PCT system in the national phase, this dietary supplement was granted patents in a number of the leading states of the world such as the United States, the European Union (a single European patent for twenty-seven countries), Canada, China, India, Israel, and Ukraine and CIS countries.
We would like to cooperate with highly qualified specialists who are looking for new approaches to the treatment of osteoporosis. We are ready to provide an objective assessment of our dietary supplement from the point view of its use by patients and, in this connection, to provide our dietary supplement for testing.
We will be glad to answer all your questions and find out your terms of possible cooperation via e-mail: dge117@mail.ru
Best Regards,
CEO of the “Parapharm” Company Elistratov Dmitry
